The latest in substance use disorders and pain management education for healthcare providers

February 2023

Hello Anna,

The Mainstreaming Addiction Treatment (MAT) and Medication Access and Training Expansion (MATE) Acts were passed in the Consolidated Appropriations Act (CAA) 2023 to expand access to and enhance substance use care across healthcare settings. According to SAMHSA and the DEA:

Effective immediately: The MAT Act removes the waiver requirement to prescribe buprenorphine for opioid use disorder. “All practitioners who have a current DEA registration that includes Schedule III authority, may now prescribe buprenorphine for Opioid Use Disorder in their practice if permitted by applicable state law and SAMHSA encourages them to do so.”
Effective June 21, 2023: The MATE Act will require prescribers of controlled substances to complete an SUD training. “SAMHSA and DEA are actively working on implementation of a separate provision of the Omnibus related to training requirements for DEA registration.”

MACS is continuing to monitor and compile guidance from state and federal agencies. Visit our website for more information...

EDUCATION

MACS ECHO Clinics | Fall/Winter Cycle

Last sessions of the winter cycle: Join our virtual ECHO learning communities for continuous case-based discussions and didactic presentations linking expert specialist teams with healthcare providers and their practices.

Maternal Health ECHO Clinic

Harm reduction during pregnancy

February 14 | 8:00 am

Opioid Treatment Program ECHO Clinic

Spring cycle starts (details coming soon)

March 1 | 12:30 pm

More information

Primary Care ECHO Clinic

Depression and opioid use disorder

February 15 | 12:30 pm

The spring cycle kicks off in March! Stay tuned for registration details.

Upcoming Trainings

pregnant person and doctor talking on couch

Psychiatric Medications in Pregnancy

Tuesday, February 7, 2023 | 12:00 pm - 1:00 pm

Opioid Use Disorder Treatment Integrated with Primary Care

Tuesday, February 14 | 12:00 pm - 2:00 pm

focus on attendees laptop screen with person presenting in background

BMC Addiction Center Webinar: Zeroing in on Xylazine

Wednesday, February 15 | 5:00 pm - 6:00 pm

NCSACW Webinar: Mitigating Safety and Risk for Children Affected by Parental Substance Use Disorders Involved in the Child Welfare System

Thursday, February 16 | 1:00 pm - 2:00 pm

In case you missed it...

CDC Opioid Guidelines: 2022 Updates Webinar

Presented by MACS Pain Management Consultant, Sarah Merritt, MD

Watch

Conferences

MDAFP Annual Meeting & Winter Refresher

MACS will be tabling

February 23- 26 | Annapolis, MD

More info

MD-DCASAM Annual Meeting

MACS team members will be tabling and presenting

March 4 | MedChi, Baltimore, MD

More info

ASAM Annual Conference: Innovations in Addiction Medicine and Science

MACS will be tabling

April 13 - 16 | National Harbor, MD

More info

NEWS

Buprenorphine Prescribing Declines in Youth as Overdoses Rise

A recent study in Pediatrics found that despite a rise in overdoses among youth between 2015 - 2020, buprenorphine prescriptions declined. Potential factors include lack of FDA approval for youth under 16 and the need for substance use training among youth-serving clinicians. Public health programs like MACS can support practitioners, including pharmacists who serve youth with substance use needs.

Physician-Delegated Unobserved Induction with Buprenorphine in Pharmacies

"In a pilot trial of pharmacy-based buprenorphine induction in Rhode Island, retention was substantially higher in a pharmacy-based follow-up buprenorphine treatment program than in usual care."